There are 2949 resources available
937P - Outcome, patterns of failure and toxicity profile following adjuvant intensity modulated radiotherapy for oral cavity squamous cell carcinomas
Presenter: Trinanjan Basu
Session: E-Poster Display
Resources:
Abstract
938P - Nutritional status (NS) as a strong predictor for immunotherapy (IT) outcome in recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) patients (pts)
Presenter: Alberto Hernando-Calvo
Session: E-Poster Display
Resources:
Abstract
939P - Evaluation of oral nano-silymarin formulation efficacy on prevention of radiotherapy induced mucositis: A randomized, double-blinded, placebo-controlled clinical trial
Presenter: Sepideh Elyasi
Session: E-Poster Display
Resources:
Abstract
940P - Analysis of a cohort of elderly patients (p) with head and neck cancer (HNC) managed within a multidisciplinary head and neck cancer unit (HNCU)
Presenter: Angelica Ferrando Diez
Session: E-Poster Display
Resources:
Abstract
941P - Efficacy and safety of apatinib combined with capecitabine in patients with advanced nasopharyngeal carcinoma
Presenter: XiuYu Cai
Session: E-Poster Display
Resources:
Abstract
942P - Genomic characterization reveals potential therapeutic targets in nasopharyngeal carcinoma with relapse
Presenter: William Cho
Session: E-Poster Display
Resources:
Abstract
943P - The most optimal induction chemotherapy regimen for loco-regionally advanced nasopharyngeal carcinoma: A network meta-analysis
Presenter: Sik Kwan Chan
Session: E-Poster Display
Resources:
Abstract
944P - The prognostic role of COP-NLR score (combination of platelet count and neutrophil to lymphocyte ratio) in locally advanced nasopharyngeal cancer patients
Presenter: Agus Achmad
Session: E-Poster Display
Resources:
Abstract
945P - Association of Epstein-Barr virus infection with peripheral immune parameters and clinical outcome in advanced nasopharyngeal carcinomas
Presenter: Dan Tao
Session: E-Poster Display
Resources:
Abstract
946P - Germinal immunogenetics and response to nivolumab in recurrent/metastatic head and neck squamous cell carcinoma (RM HNSCC) patients (pts): TopNIVO ancillary study
Presenter: Esma Saada
Session: E-Poster Display
Resources:
Abstract